| EMA number | EMEA/H/C/002735 |
| ATC code | A10BJ04 |
| Authorisation | 20 March 2014 |
| Withdrawn | 29 October 2018 |
| Revision | 8 |
Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as: Monotherapy When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance. Add-on combination therapy In combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).